# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Eric Schmidt reiterates Incyte (NASDAQ:INCY) with a Neutral.
Discovered By Incyte And Licensed To Lilly, Baricitinib Is For The Treatment Of Rheumatoid Arthritis, Alopecia Areata, Atopic D...
RBC Capital analyst Brian Abrahams reiterates Incyte (NASDAQ:INCY) with a Sector Perform and maintains $67 price target.
- Presidential Symposium to feature Phase 3 retifanlimab (Zynyz®) results in squamous cell anal carcinoma (SCAC); filing of sup...
Incyte's Phase 3 inMIND trial of Monjuvi (tafasitamab) combined with lenalidomide and rituximab meets primary endpoints in ...
- Phase 3 inMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®) or placebo in combination with lenalidomide...
The FDA has approved Incyte and Syndax Pharmaceuticals' Niktimvo for chronic graft-versus-host disease in patients after at...